Empagliflozin in Heart Failure with a Preserved Ejection Fraction

. 2021 Oct 14 ; 385 (16) : 1451-1461. [epub] 20210827

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid34449189

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In this double-blind trial, we randomly assigned 5988 patients with class II-IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. RESULTS: Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group. The effects of empagliflozin appeared consistent in patients with or without diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (407 with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88; P<0.001). Uncomplicated genital and urinary tract infections and hypotension were reported more frequently with empagliflozin. CONCLUSIONS: Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Preserved ClinicalTrials.gov number, NCT03057951).

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Citace poskytuje Crossref.org

Nejnovějších 20 citací...

Zobrazit více v
Medvik | PubMed

The treatment with soluble guanylate cyclase stimulator BAY41-8543 prevents malignant hypertension and associated organ damage

. 2025 Jun 01 ; 43 (6) : 1030-1041. [epub] 20250408

Metabolic Consequences of Advanced Chronic Heart Failure and its Modification by Implantation of a Durable Left Ventricular Assist Device

. 2024 Nov ; 25 (11) : 388. [epub] 20241031

Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement

. 2024 Aug ; 11 (4) : 1861-1874. [epub] 20240322

Effect of Sodium-Glucose Co-Transporter-2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction

. 2024 Jul ; 47 (7) : e24303.

Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure

. 2024 Jun 28 ; 23 (1) : 223. [epub] 20240628

Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases

. 2024 Apr 18 ; 73 (Suppl 1) : S377-S387. [epub] 20240418

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

. 2024 Mar 19 ; 23 (1) : 104. [epub] 20240319

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

. 2023 Mar 16 ; 22 (1) : 59. [epub] 20230316

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

. 2022 Dec ; 28 (12) : 2512-2520. [epub] 20221205

Machine Learning Approach to Understand Worsening Renal Function in Acute Heart Failure

. 2022 Nov 02 ; 12 (11) : . [epub] 20221102

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

. 2022 Mar ; 28 (3) : 568-574. [epub] 20220228

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

. 2022 Feb ; 36 (2) : 108101. [epub] 20211207

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03057951

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...